2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2010

Erdheim-Chester Disease: A Monocentric Series Of 96 Patients
Abstract Number: 1972

Erosion Case Definition and Scoring Reliability Exercise Using a New Outcome Measurement Tool, High-Resolution Peripheral Quantitative Computed Tomography, In Rheumatoid Arthritis
Abstract Number: 2885

Erosions and Sclerosis, But Not Squaring, Predict The Development Of New Syndesmophytes: A 12-Year Longitudinal Analysis (OASIS)
Abstract Number: 15

Establishment Of Standardized International Units For IgM ANTI-β₂glycoprotein Antibody Measurement
Abstract Number: 1013

Estimating the Monetary Value of annual Productivity Gained in Early Active RA Patients Receiving Etanercept Plus Methotrexate: Results From the Prize Study
Abstract Number: 1384

Estimation Of The Effect Of Denosumab On Bone Loss From The Results Of The 12-Month Phase II Study In Patients With Rheumatoid Arthritis (RA) On Background Methotrexate (MTX)
Abstract Number: 628

Estrogen Modulates The Expression Of Endosome-Associated Toll-Like Receptor 8 Through Estrogen Receptor-α Which May Contribute To Sex-Bias In Systemic Lupus Erythematosus
Abstract Number: 553

Estrogen Receptor Alpha Deficiency Protects Against Development Of Cognitive Impairment In Murine Lupus
Abstract Number: 638

Estrogen-Induced STAT1 and STAT4 Expression Is Estrogen Receptor α Dependent and IFNα Independent: A Novel Mechanism For Sex-Bias In Systemic Lupus Erythematosus Pathogenesis?
Abstract Number: 471

Etanercept 25 Mg Once Weekly Program For Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Patients In Sustained Clinical and Radiological Remission
Abstract Number: 830

Ethnic Variations At Time Of Surgery and During Follow-Up In Patients Undergoing Total Knee Arthroplasty
Abstract Number: 1751

Ethnicity-Related Differences In Behçet’s Disease In a French Multiethnic Country
Abstract Number: 514

EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) Is Increased In Sjögren’s Syndrome Patient With Fibromyalgia
Abstract Number: 2297

Evaluating Depression Questionnaires In German Rheumatoid Arthritis Patients – Preliminary Results From a Validation Study
Abstract Number: 1137

Evaluating Indeterminate Quantiferon-TB Gold In-Tube Results in Patients With Chronic Inflammatory Diseases On Immunosuppressive Therapy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].